FDA approval of the first oral PCSK9 inhibitor changes the LDL-C treatment menu

The FDA said on 17 July 2026 that Lipfendra (enlicitide) was approved as an adjunct to diet and exercise to reduce LDL-C in adults with hypercholesterolemia. The key change is the first oral PCSK9 inhibitor in a class previously centered on injectables, not proof that cardiovascular events are reduced.

Who Is Affected

The approval covers adults with hypercholesterolemia who need LDL-C reduction as an adjunct to diet and exercise, including people with heterozygous familial hypercholesterolemia. FDA frames it as an additional option for adults needing further LDL-C reduction despite existing therapies. Patients should not treat it as a self-start medicine; clinicians still need to compare statins, ezetimibe, injectable PCSK9 therapies, and overall risk.

What Changes

Lipfendra is a once-daily oral tablet that inhibits PCSK9. FDA says PCSK9 inhibitors had previously been available only as injectable therapies and calls Lipfendra the first oral drug that blocks PCSK9. Merck says the approved tablet is 20 mg. The scope is a US FDA approval; approval and reimbursement in other countries require separate checks.

Evidence

FDA’s human-drug page says efficacy and safety were demonstrated in two randomized, double-blind, placebo-controlled trials, NCT05952856 and NCT05952869, involving 3,207 adults. At week 24, LDL-C changed by -56% versus placebo in the first trial and -59% in the HeFH trial. Merck identifies the supporting studies as CORALreef Lipids and CORALreef HeFH.

Limits And Cautions

The important limit is that this is an LDL-C lowering approval. The checked approval materials do not establish that Lipfendra reduces heart attacks, strokes, or death. FDA notes diarrhea and dizziness were more common than placebo in adults with HeFH. Because high cholesterol often has no symptoms, blood testing and full cardiovascular-risk assessment come first.

Official Checks

Use the FDA press announcement for approval date, indication, and the first oral PCSK9 scope. Use FDA’s human-drug page for trial size, trial numbers, week-24 LDL-C reductions, and safety. Use Merck’s announcement to cross-check tablet strength and CORALreef trial names.

Official sources

FDA press: approval date, indication, and first oral PCSK9 scope

FDA human-drug page: trial size, week-24 LDL-C reductions, and safety

Merck announcement: tablet strength and CORALreef trial names